actimmune interferon gamma copay assistance program

A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. Horizon Pharma is currently a Zacks Rank #3 (Hold) stock. Moreover, label expansion of the drug will boost its commercial potential further.

Nevertheless, we are pleased with the company acquiring global rights to Actimmune. Horizon Pharma's shares were down 4.7% following the announcement. Top-line data is anticipated by the end of 2016.Īctimmune is also being evaluated in combination with a PD-1 checkpoint inhibitor, Bristol-Myers Squibb Company's BMY Opdivo, in an investigator-initiated phase I study for the treatment of both kidney and bladder cancer.

Earlier this month, patient enrolment in a randomized, double-blind, placebo-controlled phase III study (STEADFAST) on Actimmune for the treatment of Friedreich's ataxia was completed. Horizon Pharma is currently working on expanding the drug's label further. We note that Actimmune is the only FDA-approved treatment for chronic granulomatous disease and severe, malignant osteopetrosis. Meanwhile, Horizon Pharma has licensed the U.S., European and Canadian intellectual property rights to interferon gamma-1b for the treatment of Friedreich's ataxia under the terms of a separate agreement with an undisclosed third party. The company had earlier guided 2016 adjusted EBITDA in the range of $505 million to $520 million. Owing to this, the company now expects a reduction of approximately $10 million from the prior 2016 EBITDA guidance. Horizon Pharma said that it will immediately start investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b. We note that Horizon Pharma currently owns the rights to interferon gamma-1b, which is marketed by the company in the U.S., Canada, and Japan, under the trade name Actimmune.

Actimmune interferon gamma copay assistance program